サンプル依頼リスト カート
  • English
  • Korean
表紙：鉄欠乏性貧血の世界市場-2023年～2030年
市場調査レポート
商品コード
1345437

鉄欠乏性貧血の世界市場-2023年～2030年

Global Iron Deficiency Anemia Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
鉄欠乏性貧血の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

鉄欠乏性貧血の世界市場は、2022年に32億米ドルに達し、2023-2030年の予測期間中にCAGR 4.3%で成長し、2030年には94億米ドルに達すると予測されています。

貧血の典型的な種類のひとつである鉄欠乏性貧血（IDA）は、健康な赤血球の体内供給が不十分な場合に生じます。身体の組織は赤血球を通じて酸素を受け取っています。鉄欠乏による貧血は世界の健康問題です。鉄欠乏症の発生率とその意義について、一般の人々の認識を高めるための継続的な取り組みが行われてきました。公衆衛生キャンペーンや教育イニシアチブの目的は、危険性、徴候、早期診断と治療の意義について人々を教育することです。IDAをコントロールする上で、鉄の補助食品は依然として重要な要素であり、特に栄養摂取が不十分な場合や、体内の鉄の必要量が増加している場合（妊娠中など）には重要です。

数種類の鉄サプリメントを使用し、コンプライアンスを向上させる手法が検討されています。脱力感、倦怠感、免疫反応の低下、認知機能障害など、多くの健康問題がIDAによって引き起こされる可能性があります。深刻な状況では、心臓の問題に加え、子供の成長と発達が妨げられることもあります。医療費、生産性の低下、未治療の貧血による長期的な影響の可能性により、鉄欠乏性貧血は大きな経済的負担を強います。

ダイナミクス

製品承認と上市の増加

鉄欠乏性貧血は、あらゆる年齢層や地域の人々に影響を及ぼす世界的に広範な健康問題です。研究者やヘルスケアの専門家は、その有病率の高さから鉄欠乏性貧血に注目し、その原因や影響について詳しく研究しています。栄養に関する調査は、IDAに関する臨床調査と重なることが多いです。食習慣、栄養吸収、さまざまな食事療法が鉄の状態に与える影響などは、すべて研究のテーマです。その結果、市場拡大の原動力となっているのは、製品認可の増加です。

例えば、米国リージェント社と第一三共の声明によると、2023年06月06日、米国食品医薬品局（FDA）は、成人心不全患者の鉄欠乏症の治療にINJECTAFER（カルボキシマルトース鉄注射液）の使用を承認しました。症状の重症度によりニューヨーク心臓協会クラスII/IIIに分類される心不全患者には、運動能力を高めるために本治療が勧められます。今回、FDAは、慢性かつ進行性の疾患である心不全の成人患者に対する鉄剤の静注療法を初めて、かつ唯一承認しました。

さらに2020年3月には、経口鉄剤に不耐容の鉄欠乏性貧血患者、経口鉄剤で症状が改善しない患者、または非透析依存性慢性腎臓病患者に対する治療薬として、FDAはデリソマルトース鉄注射剤を承認しました。FDAは、デリソマルトース鉄を含む2つの非盲検無作為化臨床試験と、様々な鉄欠乏性貧血患者（計3,050人）から得られた安全性と有効性の知見に基づき、同薬を承認しました。最初の試験（FERWON-IDA）の参加者は、第二鉄デリソマルトースまたは鉄スクロースを2：1の割合で投与されるように無作為に割り付けられました。つまり、これらすべての要因が市場拡大を加速させる一助となっています。

IDAの有病率の上昇

世界の疾病負担の主な原因のひとつである鉄欠乏症は、小児、閉経前の女性、低・中所得国の住民に不釣り合いな影響を及ぼします。臨床的・機能的障害は、貧血がなくても起こり得ます。体全体の鉄貯蔵量が低下したり、感染症によって血漿からの鉄の放出が妨げられたりすると、赤芽球やその他の組織が鉄欠乏状態になります。全身の鉄ホメオスタシスの主要な調節因子であるヘプシジンは、これらの両方のシナリオで重要な役割を果たしています。

多くの場合、鉄の経口投与が第一の防御策となります。炎症時や高用量での経口鉄吸収の有効性は、鉄補給によるヘプシジンの過剰発現によって制約されます。最新の非経口鉄剤は、鉄の治療方法を大きく変え、鉄の全用量補充を迅速かつ安全に行うことができるようになっています。その結果、IDA患者の増加が市場の成長を加速させると思われます。

例えば、貧血には多くの原因があるが、最も典型的なものは鉄欠乏です。世界保健機関（WHO）によれば、鉄欠乏は世界で最も蔓延している栄養問題です。調査によると、世界中で最大80％の人が体内の鉄分が不足している可能性があります。さらに、慢性的な鉄分不足の結果、貧血に苦しむ人が30％にも上るということです。このように、これらすべてが市場拡大を後押ししています。

鉄欠乏症治療薬の副作用

鉄欠乏性貧血（IDA）の治療に使用される薬剤は、薬剤の種類や患者の治療に対する反応によって様々な悪影響を及ぼす可能性があります。鉄欠乏性貧血の治療には、鉄を含む多くのサプリメントや薬剤が使用されるが、それぞれに特有の副作用があります。

持続的な倦怠感と脱力感は、IDAの最も一般的な徴候と症状の2つです。経口鉄剤のその他の副作用には、吐き気、嘔吐、腹部不快感、下痢などがあります。これは、体の細胞が効率的に機能するのに十分な酸素を得られないために生じます。サプリメントを食事と一緒に摂取したり、摂取量を変えたりすることで、こうした悪影響が軽減されることもあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 製品承認と製品上市の増加
      • IDAの有病率の上昇
    • 抑制要因
      • IDA治療薬に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 治療タイプ別

  • 経口鉄療法
  • 非経口鉄療法
  • 赤血球輸血
  • その他

第8章 年齢層別

  • 小児
  • 成人

第9章 治療領域別

  • 産婦人科
  • 腫瘍
  • うっ血性心不全（CHF）
  • 炎症性腸疾患
  • 腎臓
  • その他

第10章 エンドユーザー別

  • 病院
  • 診療所
  • 在宅医療

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Daiichi Sankyo Company
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Novartis AG
  • Rockwell Medical Inc
  • Iron4u Aps
  • AbbVie Inc
  • Sanofi
  • Disc Medicine Inc
  • Pfizer Inc
  • Akebia Therapeutics
  • Keros Therapeutics Inc

第14章 付録

目次
Product Code: PH6780

Overview

Global Iron Deficiency Anemia Market reached US$ 3.2 billion in 2022 and is expected to reach US$ 9.4 billion by 2030, growing with a CAGR of 4.3% during the forecast period 2023-2030.

One typical kind of anaemia, iron deficiency anaemia (IDA), occurs when the body's supply of healthy red blood cells is inadequate. The body's tissues receive oxygen through red blood cells. Anaemia caused by iron deficiency is a worldwide health issue. There have been continuous initiatives to increase public awareness of its incidence and significance. The goal of public health campaigns and education initiatives is to educate people about the dangers, signs, and significance of early diagnosis and treatment. In controlling IDA, iron supplementation is still a critical component, particularly when dietary intake is insufficient or when the body's need for iron is elevated (such as during pregnancy).

It has been explored to use several types of iron supplements and compliance-improving techniques. Numerous health issues, including weakness, weariness, lowered immunological response, and cognitive impairment, can be brought on by IDA. In severe circumstances, children's growth and development can be hampered in addition to heart problems. Due to medical expenses, decreased productivity, and potential long-term effects of untreated anaemia, iron deficiency anaemia imposes a major economic burden.

Dynamics

Rising Product Approvals and Product Launches

The IDA is a widespread global health problem that affects people of all ages and communities. Researchers and healthcare experts have focused on it because of its high prevalence to learn more about its causes and effects. Research on nutrition frequently overlaps with clinical investigations on IDA. Dietary habits, nutrient absorption, and the impact of various dietary treatments on iron status are all topics of research. As a result, the market expansion is fueled by the increase in product approvals.

For instance, on June 06, 2023, The US Food and Drug Administration (FDA) approved the use of INJECTAFER (ferric carboxymaltose injection) to treat iron deficiency in adult heart failure patients, according to a statement from American Regent and Daiichi Sankyo. Patients with heart failure who are classified as New York Heart Association class II/III based on the severity of their symptoms are advised for the therapy to increase exercise capacity. The FDA has now approved an intravenous iron replacement therapy for adult patients with heart failure, a chronic and progressive condition, for the first and only time.

Moreover, in March 2020, for the treatment of people with iron deficiency anaemia who are intolerant to oral iron, whose condition has not improved with oral iron, or who have non-hemodialysis dependent chronic kidney disease, the FDA has approved the ferric derisomaltose injectable. Based on safety and efficacy findings from two open-label, randomised clinical trials including ferric derisomaltose and a total of 3,050 patients with various forms of iron deficient anaemia, the agency approved the drug. Participants in the first trial (FERWON-IDA) were randomly assigned to receive either ferric derisomaltose or iron sucrose at a 2:1 ratio. So, all of those factors aid in accelerating market expansion.

Rising Prevalence of IDA

One of the major causes of the global burden of disease, iron deficiency disproportionately affects children, premenopausal women, and residents of low- and middle-income nations. Clinical and functional deficits can happen even in the absence of anaemia, one of numerous iron shortage effects. When the body's overall iron stores are low or an infection prevents the release of iron from the plasma, erythroblasts and other tissues become iron-depleted. Hepcidin, the primary regulator of systemic iron homoeostasis, plays a key role in both of these scenarios.

In the majority of instances, oral iron therapy is the first line of defence. The effectiveness of oral iron absorption during inflammation and at high doses is constrained by hepcidin the overexpression caused by iron supplementation. Modern parenteral iron formulations have significantly changed the way that iron is treated and make total-dose iron replacement quick and safe. As a result, the increase in IDA instances will aid to accelerate market growth.

For instance, anaemia can have numerous causes, but the most typical one is iron deficiency. Iron deficiency is the most prevalent nutritional problem worldwide, according to the World Health Organisation (WHO). According to research, up to 80% of individuals worldwide may not have enough iron in their bodies. Additionally, it implies that up to 30% of people suffer from anaemia as a result of chronic iron shortage. Thus, all of these explains boost market expansion.

Side Effects Associated with IDA Drugs

Drugs used to treat iron deficiency anaemia (IDA) may have a variety of negative effects, depending on the drug type and the patient's response to the therapy. To treat IDA, many supplements and drugs containing iron are utilised, each of which has a unique set of potential side effects.

Persistent weariness and a sense of weakness are two of the most prevalent signs and symptoms of IDA. Other adverse effects of oral iron supplements include nausea, vomiting, abdominal discomfort, and diarrhoea. This happens because the body's cells are not obtaining enough oxygen to function efficiently. Sometimes taking the supplement with food or changing the dosage will help to lessen these negative effects.

Segment Analysis

The global iron deficiency anemia market is segmented based on therapy type, age group, therapy areas, end user and region.

Iron Deficiency Anemias Easily Affected to New Born Babies

There are numerous causes of iron deficient anaemia in infants and young children. For instance, young children and babies experience rapid growth and development, requiring for a substantial amount of iron. Haemoglobin, a protein in red blood cells that transports oxygen, is made possible by iron. Babies need more iron as they grow because their blood volume expands to support their growing bodies and blood supply.

Although mothers transfer some iron to their kids after birth, these stores are insufficient to meet the body's increasing demands. Iron is also found in breast milk and formula, but as a baby becomes older, their needs for iron may outgrow these sources. Caretakers occasionally postpone adding iron-rich foods to a baby's diet because they are worried about allergies or choking risks. Due to the delay, there is a higher chance of developing an iron shortage. Thus, all of these factors aid in accelerating segment expansion.

Geographical Penetration

Rising Product Approvals and Product Launches in the North American Region

Due to the well-established healthcare infrastructure, growing public awareness, and beneficial government-led programmes, North America dominates the IDA market. A significant driving force in the region is the expansion of R&D activities coupled with improved research infrastructure. Furthermore, the region dominates the IDA market due to the region's significant nutrition and supplement companies.

Additionally, rising product approvals for treatments for iron deficiency anaemia and rising corporate focus on creating efficient treatments are all expected to fuel market expansion in the region over the forecast period. For instance, on July 16, 2021, an injectable drug used to treat iron deficiency anaemia (IDA), generic Ferumoxytol is currently easily accessible in the US, according to Sandoz, a global leader in generic and biosimilar medications.

AMAG Pharmaceuticals' Feraheme (ferumoxytol injection) generic equivalent ferumoxytol is licenced to treat IDA in adult patients with chronic kidney disease, an intolerance to oral iron, or who have had an unsatisfactory response to oral iron. The whole IV iron market in the world is now worth over $1 billion and is still expanding. Thus, the aforementioned elements aid in accelerating regional growth.

COVID-19 Impact Analysis

Due to the enormous number of COVID-19 cases during the early phases of the pandemic, numerous healthcare systems encountered difficulties worldwide. Routine check-ups and screenings that were not absolutely necessary for health were frequently postponed or cancelled. This might have had an impact on the early detection and treatment of ailments like IDA. The availability of iron supplements and associated drugs needed to treat IDA may have been impacted by the global disruption of production and supply systems. It's possible that this caused shortages or distribution difficulties.

The pandemic caused other clinical trials and other research projects that were unrelated to COVID-19 to be postponed or delayed. This might have had an impact on ongoing research into IDA management and treatments. The adoption of telehealth services as a substitute for in-person visits was boosted by the pandemic. This change may have had an impact on how patients sought out medical care for IDA diagnosis and treatment.

By Therapy Type

  • Oral Iron Therapy
  • Parenteral Iron Therapy
  • Red Blood Cell Transfusion
  • Others

By Age Group

  • Pediatric
  • Adults

By Therapy Areas

  • Obstetrics and Gynecology
  • Oncology
  • Congestive Heart Failure (CHF)
  • Inflammatory Bowel Disease
  • Renal
  • Others

By End User

  • Hospitals
  • Clinics
  • Home care setting

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On May 15, 2023, Emcure Pharmaceuticals Limited (EPL) recently launched Orofer FCM 750, a new expansion of its parenteral iron brand that contains Ferric carboxymaltose (FCM), in an effort to offer patients with iron deficiency and iron deficiency anaemia (IDA) an efficient and practical treatment choice. Emcure India is the first business to introduce the 750 mg injectable form of ferric carboxymaltose. The majority of Indian patients with iron deficiency and iron deficiency anaemia (IDA) can receive a single dose of FCM up to 750 mg of iron with this innovative intervention in 15 minutes.
  • On September 09, 2022, the rights to market MonoFerric (iron isomaltoside) injections in India and Nepal have been acquired by Zydus Lifesciences Ltd. from Pharmacosmos A/S, a Danish company. Iron isomaltoside 1000 solution for injection or infusion, also known as MonoFerric, is a fast, single-dose IV iron with an excellent safety profile that can be administered up to 20 mg/kg of body weight.
  • On March 24, 2021, the pharmaceuticals and medical devices agency (PMDA) has provided the go-ahead for Riona Tablets 250mg (Riona), also known as ferric citrate hydrate in Japan, to be used in the treatment of adult patients with iron deficiency anaemia (IDA), according to Akebia Therapeutics, Inc.

Competitive Landscape

The major global players in the market include: Daiichi Sankyo Company, Novartis AG, Rockwell Medical Inc, Iron4u Aps, AbbVie Inc, Sanofi, Disc Medicine Inc, Pfizer Inc, Akebia Therapeutics, Keros Therapeutics Inc and among others.

Why Purchase the Report?

  • To visualize the global iron deficiency anemia market segmentation based on therapy type, age group, therapy areas, end user and region,as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of iron deficiency anemia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global Iron Deficiency Anemia market report would provide approximately 61tables, 58figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Therapy Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by Therapy Areas
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising product approvals and product launches
      • 4.1.1.2. Rising prevalence of IDA
  • 4.2. Restraints
      • 4.2.1.1. Side Effects associated with IDA drugs
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Therapy Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 7.1.2. Market Attractiveness Index, By Therapy Type
  • 7.2. Oral Iron Therapy *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Parenteral Iron Therapy
  • 7.4. Red Blood Cell Transfusion
  • 7.5. Others

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Pediatric *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Adults

9. By Therapy Areas

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Areas
    • 9.1.2. Market Attractiveness Index, By Therapy Areas
  • 9.2. Obstetrics and Gynecology *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Oncology
  • 9.4. Congestive Heart Failure (CHF)
  • 9.5. Inflammatory Bowel Disease
  • 9.6. Renal
  • 9.7. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Clinics
  • 10.4. Home care setting

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Areas
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Areas
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Areas
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Areas
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Areas
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Daiichi Sankyo Company *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Novartis AG
  • 13.3. Rockwell Medical Inc
  • 13.4. Iron4u Aps
  • 13.5. AbbVie Inc
  • 13.6. Sanofi
  • 13.7. Disc Medicine Inc
  • 13.8. Pfizer Inc
  • 13.9. Akebia Therapeutics
  • 13.10. Keros Therapeutics Inc

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us